Date of prep: December 2020
Prescribing information and
adverse events reporting
For healthcare professionals only
In response to the following article:
Dear PIP editor,
The initiative announced by Keith Ridge is really welcome and enables community pharmacists in NHS England to contribute more to the care of people with Hepatitis C, in the same way, that community pharmacists in NHS Wales are already doing.
Hepatitis C has been getting lots of media attention recently, with the announcement by NHS Tayside that they have eliminated hepatitis C and met the WHO target, well ahead of 2030 the deadline. In Tayside, community pharmacists played a crucial part in this success, by testing, diagnosing and treating patients, all within the pharmacy.
Just today, the protocol for the REACH study was published in BMJ Open. This study evaluates how PCR tests which show the presence of active infection with Hepatitis C can be carried out in community pharmacies in Scotland, Wales and Australia!
So community pharmacy will be making a great contribution to the elimination of a disease that causes cirrhosis and liver cancer amongst some of the most disadvantaged groups in the United Kingdom.
Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial.
Pharmacy in Practice is a UK pharmacy publication with its roots in Scotland.